In this study, the PI3K inhibitors reduced the cell proliferation of two HER2-positive breast cancer cell lines, where SK-BR-3 exhibited more susceptibility to alpelisib or inavolisib than HCC1569 (Fig. 1b). This evidence concerns the gene ERBB2 and breast cancer.